Organogenesis Holdings Inc (ORGO)vsTeva Pharma Industries Ltd ADR (TEVA)
ORGO
Organogenesis Holdings Inc
$2.44
+1.24%
HEALTHCARE · Cap: $317.74M
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2959% more annual revenue ($17.26B vs $564.17M). TEVA leads profitability with a 8.2% profit margin vs 6.6%. ORGO trades at a lower P/E of 16.5x. TEVA earns a higher WallStSmart Score of 73/100 (B).
ORGO
Strong Buy67
out of 100
Grade: B-
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$7.02
Current Price
$2.44
$4.58 discount
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.6% margin — thin
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 78.1% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
ORGO profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.39 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 67/100) and 11.4% revenue growth. ORGO offers better value entry with a 46.7% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?